209 related articles for article (PubMed ID: 30778950)
1. Real World Experience of Treating Neuroblastoma: Experience from a Tertiary Cancer Centre in India.
Radhakrishnan V; Raja A; Dhanushkodi M; Ganesan TS; Selvaluxmy G; Sagar TG
Indian J Pediatr; 2019 May; 86(5):417-426. PubMed ID: 30778950
[TBL] [Abstract][Full Text] [Related]
2. A Retrospective Analysis of the Therapeutic Outcomes of 117 Neuroblastoma Patients Treated at a Single Pediatric Oncology Center in China.
Yu U; Xu H; Chen S; Yi M; Liu C; Zhang X; Wang C; Song J; Gan Y; Wang J; Wang Y; Zhang Q; Sun J; Xia B; Zhang G; Li C; Wen F; Liu S; Yuan X
Cancer Control; 2023; 30():10732748231187837. PubMed ID: 37575028
[TBL] [Abstract][Full Text] [Related]
3. Retinoic acid post consolidation therapy for high-risk neuroblastoma patients treated with autologous hematopoietic stem cell transplantation.
Peinemann F; van Dalen EC; Tushabe DA; Berthold F
Cochrane Database Syst Rev; 2015 Jan; 1():CD010685. PubMed ID: 25634649
[TBL] [Abstract][Full Text] [Related]
4. Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin.
Kushner BH; Ostrovnaya I; Cheung IY; Kuk D; Modak S; Kramer K; Roberts SS; Basu EM; Yataghene K; Cheung NK
Oncotarget; 2016 Jan; 7(4):4155-66. PubMed ID: 26623730
[TBL] [Abstract][Full Text] [Related]
5. Survival Benefit of Myeloablative Therapy with Autologous Stem Cell Transplantation in High-Risk Neuroblastoma: A Systematic Literature Review.
Żebrowska U; Balwierz W; Wechowski J; Wieczorek A
Target Oncol; 2024 Mar; 19(2):143-159. PubMed ID: 38401028
[TBL] [Abstract][Full Text] [Related]
6. Neuroblastoma: outcome over a 14 year period from a tertiary care referral centre in India.
Agarwala S; Mandelia A; Bakhshi S; Srinivas M; Bajpai M; Gupta AK; Gupta DK; Bhatnagar V
J Pediatr Surg; 2014 Aug; 49(8):1280-5. PubMed ID: 25092090
[TBL] [Abstract][Full Text] [Related]
7. [Comprehensive protocol for diagnosis and treatment of childhood neuroblastoma--results of 45 cases].
Tang JY; Pan C; Chen J; Xu M; Chen J; Xue HL; Gu LJ; Dong R; Ye H; Zhou M; Wang YP
Zhonghua Er Ke Za Zhi; 2006 Oct; 44(10):770-3. PubMed ID: 17229383
[TBL] [Abstract][Full Text] [Related]
8. Management and outcome of stage 3 neuroblastoma.
Modak S; Kushner BH; LaQuaglia MP; Kramer K; Cheung NK
Eur J Cancer; 2009 Jan; 45(1):90-8. PubMed ID: 18996003
[TBL] [Abstract][Full Text] [Related]
9. Overall survival for neuroblastoma in South Africa between 2000 and 2014.
Van Heerden J; Hendricks M; Geel J; Sartorius B; Hadley GP; Du Plessis J; Büchner A; Naidu G; Van Emmenes B; Van Zyl A; Kruger M
Pediatr Blood Cancer; 2019 Nov; 66(11):e27944. PubMed ID: 31368239
[TBL] [Abstract][Full Text] [Related]
10. Is there a benefit of 131 I-MIBG therapy in the treatment of children with stage 4 neuroblastoma? A retrospective evaluation of The German Neuroblastoma Trial NB97 and implications for The German Neuroblastoma Trial NB2004.
Schmidt M; Simon T; Hero B; Eschner W; Dietlein M; Sudbrock F; Bongartz R; Berthold F; Schicha H
Nuklearmedizin; 2006; 45(4):145-51; quiz N39-40. PubMed ID: 16964339
[TBL] [Abstract][Full Text] [Related]
11. Local Control and Clinical Outcome of High-risk Pediatric Neuroblastoma Patients After Receiving Multimodality Treatment and Helical Tomotherapy.
Chen GY; Cheng JC; Chen YH; Lu MY; Chang HH; Yang YL; Jou ST; Hsu WM; Kuo SH
Anticancer Res; 2019 Apr; 39(4):2207-2215. PubMed ID: 30952769
[TBL] [Abstract][Full Text] [Related]
12. [Clinical characteristics and prognostic analysis of 458 children with high-risk neuroblastoma in a single center].
Su Y; Ma XL; Wang HM; Qin H; Qin MQ; Zhang FQ; Jin M; Zhang DW; Chen CH; Zeng Q; He LJ; Ni X
Zhonghua Er Ke Za Zhi; 2020 Oct; 58(10):796-801. PubMed ID: 32987457
[No Abstract] [Full Text] [Related]
13. Long-Term Outcomes and Safety Trends of Autologous Stem-Cell Transplantation in Non-Hodgkin Lymphoma: A Report From A Tertiary Care Center in India.
Kumar S; Sharma A; Pramanik R; Pathak N; Gogia A; Kumar A; Kayal S; Sharma V; Sahoo RK; Thulkar S; Sharma MC; Gupta R; Mallick S; Thomas M; Raina V
JCO Glob Oncol; 2022 May; 8():e2100383. PubMed ID: 35561291
[TBL] [Abstract][Full Text] [Related]
14. Outcome in neuroblastoma.
Ozguven AA; Anak S; Unuvar A; Akcay A; Karakas Z; Ozturk G; Devecioglu O; Agaoğlu L
Indian J Pediatr; 2015 May; 82(5):450-7. PubMed ID: 25274444
[TBL] [Abstract][Full Text] [Related]
15. Outcomes and complications of surgery in patients with intermediate-risk neuroblastoma: experience from an Indian tertiary Cancer Centre.
Qureshi SS; Bhagat M; Harris C; Chinnaswamy G; Vora T; Kembhavi S; Prasad M; Ramadwar M; Shetty O; Laskar S; Khanna N; Amin N; Talole S
Pediatr Surg Int; 2018 Apr; 34(4):435-442. PubMed ID: 29487992
[TBL] [Abstract][Full Text] [Related]
16. High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma.
Yalçin B; Kremer LC; Caron HN; van Dalen EC
Cochrane Database Syst Rev; 2013 Aug; (8):CD006301. PubMed ID: 23970444
[TBL] [Abstract][Full Text] [Related]
17. Influence of image-defined risk factors on the outcome of patients with localised neuroblastoma. A report from the LNESG1 study of the European International Society of Paediatric Oncology Neuroblastoma Group.
Monclair T; Mosseri V; Cecchetto G; De Bernardi B; Michon J; Holmes K
Pediatr Blood Cancer; 2015 Sep; 62(9):1536-42. PubMed ID: 25663103
[TBL] [Abstract][Full Text] [Related]
18. Validation of prognostic factors and survival of patients with multiple myeloma in a real-life autologous stem cell transplantation setting: a Swiss single centre experience.
Samaras P; Blickenstorfer M; Haile SR; Siciliano RD; Petrausch U; Mischo A; Zweifel M; Honegger H; Schanz U; Stussi G; Taverna C; Bauer S; Knuth A; Stenner-Liewen F; Renner C
Swiss Med Wkly; 2011; 141():w13203. PubMed ID: 21630163
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of post-induction therapy for high-risk neuroblastoma patients with end-induction residual disease.
Desai AV; Applebaum MA; Karrison TG; Oppong A; Yuan C; Berg KR; MacQuarrie K; Sokol E; Hall AG; Pinto N; Wolfe I; Mody R; Shusterman S; Smith V; Foster JH; Nassin M; LaBelle JL; Bagatell R; Cohn SL
Cancer; 2022 Aug; 128(15):2967-2977. PubMed ID: 35665495
[TBL] [Abstract][Full Text] [Related]
20. Thiotepa and melphalan based single, tandem, and triple high dose therapy and autologous stem cell transplantation for high risk neuroblastoma.
Saarinen-Pihkala UM; Hovi L; Koivusalo A; Jahnukainen K; Karikoski R; Sariola H; Wikström S
Pediatr Blood Cancer; 2012 Dec; 59(7):1190-7. PubMed ID: 22492714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
